Newswire (Published: Tuesday, April 25, 2017, Received: Friday, April 21, 2017, 3:38:44 AM CDT)
Word Count: 560
Researchers from Department of Urology Discuss Findings in Prostate Cancer (The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality)
By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news originating from Baltimore, Maryland, by NewsRx correspondents, research stated, "Gleason score is one of the most important prognostic indicators for prostate cancer. Downgrading from biopsy Gleason score 7 to radical prostatectomy Gleason score 6 occurs commonly and yet to our knowledge the impact on survival outcomes is unknown."
Our news journalists obtained a quote from the research from the Department of Urology, "We examined biochemical recurrence and prostate cancer specific mortality risk in a large cohort evaluated by a single group of expert urological pathologists. Of 23,918 men who underwent radical prostatectomy at our institution between 1984 and 2014, 10,236 with biopsy and radical prostatectomy Gleason score 6 or 7 without upgrading were included in analysis. The cohort was divided into 3 groups, including group 1-biopsy and radical prostatectomy Gleason score 6 in 6,923 patients (67.6%), group 2-Gleason score 7 downgraded to radical prostatectomy Gleason score 6 in 648 (6.3%) and group 3dbiopsy and radical prostatectomy Gleason score 7 in 2,665 (26.0%). Biochemical recurrence and prostate cancer specific mortality risks were compared using Cox regression and competing risk analyses adjusting for clinicopathological variables. At a median followup of 5 years (range 1 to 29), 992 men experienced biochemical recurrence and 95 had died of prostate cancer. Biochemical recurrence- free survival in downgraded cases (group 2) was better than in group 3 cases, which had Gleason score 7 on biopsy and radical prostatectomy (p < 0.001), but worse than group 1 cases, which had Gleason score 6 on biopsy and radical prostatectomy (p < 0.001). Downgrading was independently associated with biochemical recurrence (adjusted HR 1.87, p< 0.0001) but not with prostate cancer specific mortality (adjusted HR 1.65, p = 0.636)."
According to the news editors, the research concluded: "Downgrading from biopsy Gleason score 7 to radical prostatectomy Gleason score 6 was an independent predictor of biochemical recurrence but not prostate cancer specific mortality, likely due to the presence of minor amounts of Gleason pattern 4."
For more information on this research see: The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. Journal of Urology, 2017;197(4):1060-1066. Journal of Urology can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA. (Elsevier - www.elsevier.com; Journal of Urology - www.journals.elsevier.com/journal-of-urology/)
The news correspondents report that additional information may be obtained from M. Han, James Buchanan Brady Urol Inst, Dept. of Urol, Baltimore, MD, United States. Additional authors for this research include H.J. Chalfin, Z.Y. Feng, B.J. Trock, J.I. Epstein, C. Cheung, E. Humphreys, A.W. Partin and M. Han (see also Oncology - Prostate Cancer).
Keywords for this news article include: Baltimore, Maryland, United States, North and Central America, Cancer, Risk and Prevention, Prostatic Neoplasms, Prostate Cancer, Prostatectomy, Biochemicals, Biochemistry, Chemicals, Oncology, Surgery, Department of Urology.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC
New York City
Science and Technology
Health and Wellness
Medical Conditions and Diseases
Men's Health Issues
Medical Specialties and Practices
Treatments and Therapies